Literature DB >> 7102710

Species differences in the disposition of acyclovir.

P de Miranda, H C Krasny, D A Page, G B Elion.   

Abstract

The disposition of acyclovir was investigated in several species. The drug was well distributed into all the tissues, including the brain, in mice and rats. Binding of acyclovir to plasma proteins was 36 percent or lower. After intravenous bolus dosing (20 mg/kg) in dogs, the plasma acyclovir concentration-time profile, determined by radioimmunoassay, showed a biphasic decline with a half-life in the elimination phase of 2.3 +/- 0.1 hours. The volume of distribution (Vd beta) of 1.2 +/- 0.2 liters/kg indicated distribution of drug into the tissues. Marked species differences were observed in the gastrointestinal absorption and biotransformation of acyclovir. Oral dosing produced better absorption in dogs and mice than in rats and rhesus monkeys. More than 95 percent of the radioactivity in the urine derived from a 14C-acyclovir parenteral dose was recovered as the unchanged drug in mice, rats, and dogs. Minor urinary metabolites were characterized by high-performance liquid chromatography as 9-carboxymethoxymethylguanine (CMMG) and 8-hydroxy-9-(2-hydroxyethoxymethyl)guanine. In other species--guinea pig, rabbit, and rhesus monkey--up to 40 percent of the radioactivity in the urine consisted of these metabolites.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7102710     DOI: 10.1016/0002-9343(82)90059-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

1.  Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.

Authors:  Ismail A Attia; Sanaa A El-Gizawy; Medhat A Fouda; Ahmed M Donia
Journal:  AAPS PharmSciTech       Date:  2007-12-14       Impact factor: 3.246

Review 2.  Clinical pharmacokinetics of acyclovir.

Authors:  O L Laskin
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

3.  Efficacy of 2'-nor-2'-deoxyguanosine treatment for orofacial herpes simplex virus type 1 skin infections in mice.

Authors:  M E Davies; J V Bondi; A K Field
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

4.  Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.

Authors:  Ulrich A K Betz; Rüdiger Fischer; Gerald Kleymann; Martin Hendrix; Helga Rübsamen-Waigmann
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 5.  Antiherpes drugs: promises and pitfalls.

Authors:  E de Clercq
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

6.  Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.

Authors:  Jan Lycke; Clas Malmeström; Lars Ståhle
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

7.  Estimation of skin target site acyclovir concentrations following controlled (trans)dermal drug delivery in topical and systemic treatment of cutaneous HSV-1 infections in hairless mice.

Authors:  G Imanidis; W Q Song; P H Lee; M H Su; E R Kern; W I Higuchi
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

Review 8.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

Review 9.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

10.  Transdermal Film Loaded with Garlic Oil-Acyclovir Nanoemulsion to Overcome Barriers for Its Use in Alleviating Cold Sore Conditions.

Authors:  Alshaimaa M Almehmady; Sarah A Ali
Journal:  Pharmaceutics       Date:  2021-05-07       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.